Fetal Growth Restriction
Conditions
Keywords
fetal growth restriction, left lateral position, maternal fetal medicine
Brief summary
The goal of this clinical trial is to learn if maternal left-lateral positioning in pregnancy works to treat fetal growth restriction. This study will also help us learn about the effects of left-lateral positioning on maternal metabolomics, maternal mental health, fetal cardiac function, and delivery outcomes. The main questions it aims to answer are: * Does maternal left-lateral position in a pregnancy with fetal growth restriction improve the baby's growth? * How are maternal metabolomics, delivery outcomes, maternal mental health, and fetal cardiac function impacted by maternal left-lateral position? Researchers will compare the intervention group to pregnancies with fetal growth restriction that receive standard of care (without left-lateral positioning) to see if left-lateral position improves fetal biometry in fetal growth restriction. Participants will: * Practice left-lateral position every day for 4 hours (cumulatively) with 10-mins stretching after every hour of left-lateral position, or continue to receive standard of care * Visit the clinic once after 4 weeks for a follow-up research visit, and at the time of delivery Tracking of the physical activity and adherence to left-lateral position at home in intervention group A will be done through a fitbit (smart watch) given during enrollment. A fitbit will also be given to participants in intervention group B, receiving standard of care, to monitor their physical activity trends at home.
Interventions
Left-lateral position is the recommended position of resting in pregnancy. The participants in the intervention group will be advised to practice this position with an intermittent 10-minute stretching after every hour of resting, with no more than 4-hours of this intervention per day.
Sponsors
Study design
Masking description
The sonographer doing the fetal biometry at enrollment and during the 4-week follow-up visit will be masked to the study group assigned to the participant.
Eligibility
Inclusion criteria
* Pregnant persons between 18 - 65 years of age, with a diagnosis of fetal growth restriction, with an estimated fetal weight less than tenth percentile * Participants with a singleton pregnancy between 24- and 34-weeks' gestational age * Participants with fluency in English or Spanish language
Exclusion criteria
* Patients with a known history of deep vein thrombosis, pulmonary embolism, or hypercoagulability disorder * Patients with a pre-pregnancy BMI greater than 40 * Pregnancy with severe abnormality in umbilical artery Doppler flow, including absent end-diastolic flow (AEDF) and reverse end-diastolic flow (REDF) * Patients receiving anticoagulation therapy * Pregnancy with suspected chromosomal anomalies or a multifetal pregnancy * Patients with an active smoking status during pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fetal biometry | 4 weeks after enrollment | Fetal estimated fetal weight and abdominal circumference will be assessed and compared to enrollment values |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fetal cardiac function | 4 weeks after enrollment | Variables of fetal cardiac function including cardiac contractility and cardiac size and shape will be assessed using speckle tracking |
| Feto-Maternal Doppler flow | 4 weeks after enrollment | Measures of Doppler flow including umbilical artery, middle cerebral artery, umbilical vein flow, and cerebroplacental ratio will be assessed |
| Delivery outcomes | At delivery | Variables including gestational age at delivery, birthweight, neonatal arterial pH, APGAR scores, mode of delivery, indication of cesarean delivery, if applicable, will be recorded |
| Maternal Mental Health evaluation | 4 weeks after enrollment, and after delivery | Maternal mental health assessment will be done via Edinburg Postnatal Depression Scale questionnaire. Based on questionnaire responses, participant will receive a score within range 0-30. A score of 10 or higher would require further evaluation for depression. |
| Maternal Metabolomics assessment | 4 weeks after enrollment, and after delivery | Maternal metabolomics will be evaluated and compared to baseline via a blood and a urine sample at the 4-week follow-up and via a cord blood and a maternal blood sample at the time of delivery. |
Countries
United States